We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: FDA Approves Roche/Genentech Drug Erivedge to Treat Advanced Skin Cancer Not Treatable with Surgery
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > FDA Approves Roche/Genentech Drug Erivedge to Treat Advanced Skin Cancer Not Treatable with Surgery
BusinessNews

FDA Approves Roche/Genentech Drug Erivedge to Treat Advanced Skin Cancer Not Treatable with Surgery

BarbaraDuck
BarbaraDuck
Share
0 Min Read
SHARE

Basal cell carcinoma is rarely fatal and in many cases surgery is the cure but in some patients is can spread beyond the skin area in to other areas of the body and this is where the new oral drug comes in to help fight and shrink tumors.  image

When the cancer has metastasized, this is about the only option available.  There are a few side effects like loss of hair and food tasting different but the benefits seem to certainly outweigh. The pill is taken once a day and the cost will be around $7k a month.  I do hope insurers start to cover this as it has been an issue in California with covering oral cancer medications.  BD

California Legislature Urging Health Insurance Companies to Cover Chemotherapy–Especially With Breast Cancer Treatments

 

The Food and Drug Administration has for the first time approved a drug to treat advanced cases of the most common skin cancer, basal cell carcinoma, the agency announced Monday.

The drug, a capsule called Erivedge (generically known as vismodegib), treats basal cell carcinoma that has metastasized (spread through the body), or that cannot be treated with surgery.

In a clinical study in 96 people, 30 percent of those with locally advanced basal cell carcinoma (which had spread to surrounding tissue), and 43 percent of those with metastatic cancer (which had spread to distant sites in the body) saw their tumors shrink or heal while taking the drug, according to a statement from the FDA. Patients took one pill by mouth each day. 

Doctors treat non-metastatic cases with surgery, radiation or topical treatments, and have an extremely high success rate. But no other treatments exist for inoperable cases, such as people with tumors that have extended into the brain, or people who would become disfigured from surgery

Basal cell carcinoma is linked to mutations in genes that are part of a signaling pathway called the hedgehog pathway. Erivedge works by inhibiting the hedgehog pathway.

http://vitals.msnbc.msn.com/_news/2012/01/31/10280479-fda-approves-first-drug-for-inoperable-skin-cancer

More Read

Product Shot of Gene-RADAR
Little Things Do Make a Big Difference: Globalizing Personal Health
The First Amendment, in Your Medicine Cabinet
3 Hidden Effects Personal Injury Lawsuits Have on Your Health
Super Nurse: 4 Pointers to Help You Become a Truly Extraordinary Nurse
Pre and Post Operative Nutritional Considerations…

 

TAGGED:basal cell carcinomaErivedgeFDAskin cancer
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

Flat editorial illustration: The article's core relationship is that substantial clinical testing of thymosin alpha-1 did not est
Thymosin Alpha-1 Got the Big Trials Most Peptides Never Get
Global Healthcare
October 12, 2026
Flat editorial illustration: The article examines how researchers study tissue repair through growth factors and peptide-based re
How Researchers Study Tissue Repair: From Growth Factors to Peptide-Based Research
Health
October 12, 2026
Workers Comp Claim Denied – Now What?  -- AI-generated illustration
Workers Comp Claim Denied – Now What? 
Policy & Law
October 9, 2026
The Case for Proactive Nutrient Support and Where IV Therapy Fits In -- AI-generated illustration
The Case for Proactive Nutrient Support and Where IV Therapy Fits In
Health Therapies
October 5, 2026

You Might also Like

Accountable Care Organization (ACO)
BusinessFinanceHospital AdministrationPolicy & Law

Are ACOs Just HMOs in Disguise?

August 17, 2014

Automation in Digital Credentialing

February 23, 2016

Health Care Reform in 2 Short Sentences

July 21, 2011

5 Laws of Innovation and Adoption for Telehealth / mHealth

February 26, 2013
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?